Phase I & II clinical trial expertise

Our substantial experience of developing and conducting adaptive protocols for Phase I and II trials enables us to maximise the return on our sponsors’ studies whilst guaranteeing the safety of our participants.

x

Benefits of using our Phase I & II clinical trials

Adding value by gathering more and highly relevant data. We only collect and analyse essential data to meet the trial objectives within a limited budget.

We limit assessments and participant exposure to what is relevant and essential. Tailoring our adaptive limits and control mechanisms for each protocol to manage potential risks.

Umbrella protocols to maximise efficiency. We integrate ethnic comparison elements, intensive cardiac assessments, and other biomarkers into a combined umbrella protocol - avoiding potential risks in further drug development.

We maximise return on our sponsors' trials

Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.

Get in touch today

Why choose Richmond Pharmacology for your Early Phase Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Systematic and logical protocols

We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.

Read more +

Competent and fast decisions

We guarantee rapid progression of your trial.

Read more +

Rapid approval

We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.

Read more +

Time efficient

Fast and efficient adaptive protocol development using a transparent and systematic approach.

Read more +

Our adaptive protocols enable immediate implementation of adaptive changes leading to early decision making and efficient use of essential data outputs.

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event